SPHK2 and metabolic dysfunction-associated steatotic liver disease: In summary, SphK2, as an indispensable factor in the cross-regulation of lipid metabolism and epigenetics in NAFLD-HCC, offers new therapeutic strategies through targeted intervention (such as gene ablation or inhibitor application).